Last updated: April 21, 2026
Quick Answer
A Tesa/IPA blend peptide combines tesa and ipamorelin into a single research formulation designed to stimulate growth hormone release through two distinct pathways. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog, while ipamorelin is a growth hormone secretagogue that acts on ghrelin receptors. Together in a blend, these peptides have been studied for their potential synergistic effects on GH pulsatility, body composition markers, and metabolic function in preclinical and clinical research contexts.
Key Takeaways
- A Tesa/IPA blend peptide combines two growth hormone-stimulating compounds with different mechanisms of action.
- Tesamorelin is FDA-approved (as Egrifta) specifically for HIV-associated lipodystrophy, giving it a stronger clinical evidence base than most research peptides.
- Ipamorelin is a selective GH secretagogue that does not significantly raise cortisol or prolactin levels in studied doses, based on published research.
- Blending these two peptides targets both the GHRH receptor and the ghrelin receptor, which may produce a more robust GH pulse than either peptide alone.
- Peptide blends are sold for research purposes; they are not approved for human therapeutic use outside of specific FDA-cleared indications.
- Purity, third-party testing, and proper reconstitution are critical factors when sourcing any peptide blend for laboratory research.
- Dosing protocols in research settings vary widely; there is no single standardized protocol for the combined blend.
What Is a Tesa/IPA Blend Peptide?
A Tesa/IPA blend peptide is a pre-mixed research compound containing tesa and ipamorelin in a single lyophilized vial. Rather than reconstituting and administering each peptide separately, the blend provides both compounds in one preparation.
Tesamorelin is a 44-amino-acid synthetic analog of growth hormone-releasing hormone. The FDA approved it in 2010 under the brand name Egrifta for reducing excess abdominal fat in HIV-positive patients with lipodystrophy. Its mechanism works by binding to GHRH receptors in the anterior pituitary gland, signaling the release of endogenous growth hormone.
Ipamorelin is a pentapeptide (five amino acids) that acts as a selective growth hormone secretagogue. It binds to the ghrelin receptor (GHS-R1a) in the pituitary. Research published in the European Journal of Endocrinology (Raun et al., 1998) showed that ipamorelin stimulates GH release without significantly affecting ACTH, cortisol, or prolactin at GH-releasing doses, making it one of the more selective secretagogues studied.
When combined, the blend targets two separate receptor systems simultaneously. This dual-pathway approach is the primary reason researchers and biohackers are interested in the Tesa/IPA blend peptide formulation.
For those exploring the broader category, check out the full selection of peptide blends for research.
How Does the Tesa/IPA Blend Peptide Work?
The blend works by activating two complementary signaling pathways in the pituitary gland to amplify growth hormone output.
Here's a simplified breakdown:
| Component | Receptor Target | Primary Action | Selectivity |
|---|---|---|---|
| Tesamorelin | GHRH receptor | Stimulates GH synthesis and release | Specific to GH axis |
| Ipamorelin | Ghrelin receptor (GHS-R1a) | Amplifies GH pulse magnitude | Selective; minimal cortisol/prolactin impact |
Why two pathways matter: GHRH and ghrelin receptor agonists work through different intracellular signaling cascades. GHRH primarily uses the cAMP/PKA pathway, while ghrelin receptor activation involves phospholipase C and intracellular calcium release. When both pathways fire at once, research suggests the resulting GH pulse can be larger than the sum of each peptide's individual effect. This concept of synergistic GH release has been documented in studies examining GHRH analogs combined with GH secretagogues (Bowers, 1998).
This is also why some researchers explore tesa combined with CJC-1295 and ipamorelin in triple-blend formulations, adding a third mechanism through DAC-modified GHRH analogs.
Explore our most popular products for sale to see which peptide formulations are trending among researchers.
What Has Research Found About Tesamorelin and Ipamorelin Individually?
Before evaluating the blend, it helps to understand what the published literature says about each component on its own.
Tesamorelin Research Findings
- Body composition: In the LIPO-010 and LIPO-011 trials (Falutz et al., 2007; Falutz et al., 2008), tesa reduced visceral adipose tissue by approximately 15-18% over 26 weeks in HIV-positive subjects with lipodystrophy.
- IGF-1 levels: Tesamorelin consistently raised IGF-1 into the upper-normal physiological range in clinical trials without pushing levels into supraphysiological territory at standard doses.
- Cognitive function: A 2012 study (Baker et al., Archives of Neurology) found that tesa improved executive function and verbal memory in older adults with mild cognitive impairment or healthy cognition.
For a deeper look at the compound alone, see our tesa peptide benefits overview.
Ipamorelin Research Findings
- GH release: Raun et al. (1998) demonstrated dose-dependent GH release in animal models with high selectivity.
- Bone density: Anderson et al. (2001) published findings in Bone showing ipamorelin increased bone mineral content in ovariectomized rats, a model for post-menopausal bone loss.
- GI motility: Ipamorelin has been studied for post-operative ileus, with Phase II trial data showing potential for accelerating bowel recovery after surgery (Helsinn Therapeutics, 2008).
Learn more about ipamorelin as a standalone research peptide.
Who Is Researching the Tesa/IPA Blend Peptide and Why?
The Tesa/IPA blend peptide attracts interest from several distinct groups:
- Longevity researchers studying age-related GH decline (somatopause) and its relationship to body composition, sleep quality, and metabolic markers.
- Fitness-oriented biohackers interested in the peptide's potential effects on lean mass preservation and fat metabolism, based on the individual components' research profiles.
- Academic labs investigating pituitary signaling, GH pulsatility patterns, and receptor cross-talk between GHRH and ghrelin pathways.
- Clinical researchers exploring whether combination GH secretagogue therapy could offer advantages over monotherapy in specific patient populations.
Choose this blend if the research question involves dual-pathway GH stimulation and the goal is to study synergistic effects. Choose individual peptides if the research requires isolating the contribution of a single mechanism.
How Is the Tesa/IPA Blend Peptide Typically Dosed in Research?
There is no universally standardized dosing protocol for the Tesa/IPA blend peptide because it is a research compound, not an FDA-approved drug in blend form. However, dosing ranges from published studies on each individual component provide a reference framework:
| Peptide | Commonly Studied Dose Range | Frequency in Studies |
|---|---|---|
| Tesamorelin | 1-2 mg/day (clinical trials) | Once daily, typically morning |
| Ipamorelin | 100-300 mcg per administration | 1-3 times daily in preclinical models |
Common mistake: Assuming that blend ratios are standardized across all vendors. They are not. A 12mg blend vial might contain different ratios of tesa to ipamorelin depending on the supplier. Always verify the exact composition per vial before designing a research protocol.
For specific reconstitution guidance, see our Tesa/CJC/IPA blend reconstitution guide.
What Are the Potential Benefits and Limitations?
Potential Benefits (Based on Individual Component Research)
- Amplified GH pulsatility through dual receptor activation
- Selective GH release without significant cortisol or prolactin elevation (ipamorelin's selectivity profile)
- Visceral fat reduction signals observed in tesa clinical trials
- Convenience of a single-vial preparation for research protocols
- Potential cognitive and metabolic secondary effects based on tesa's published data
Known Limitations and Cautions
- No published clinical trials on the specific tesa + ipamorelin blend as a combined product
- Stability questions: Combining two peptides in one solution may affect shelf life or bioactivity; third-party testing is essential
- Regulatory status: The blend is sold for research use only and is not approved for human therapeutic use
- Individual variation: GH response varies significantly based on age, body composition, and existing pituitary function
- Cost: Blends are typically more expensive per vial than individual components purchased separately
Browse what's new in peptide research for the latest developments in this space.
How Does the Tesa/IPA Blend Compare to Other Peptide Blends?
Researchers often weigh the Tesa/IPA blend peptide against other popular combinations. Here's a quick comparison:
| Blend | Components | Unique Angle |
|---|---|---|
| Tesa/IPA | Tesamorelin + Ipamorelin | Dual-pathway GH release, tesa has FDA data |
| Tesa/CJC/IPA | Tesamorelin + CJC-1295 + Ipamorelin | Triple pathway; CJC-1295 extends GH release duration |
| Tesa/AOD/CJC/IPA | Tesamorelin + AOD-9604 + CJC-1295 + Ipamorelin | Adds AOD-9604's lipolytic fragment |
| CJC/IPA (no Tesa) | CJC-1295 + Ipamorelin | Lower cost entry point; no GHRH analog with clinical trial backing |
Decision rule: If the research priority is studying the strongest evidence-backed GHRH analog paired with a selective secretagogue, the Tesa/IPA blend is the most focused option. For broader multi-mechanism studies, a triple or quad blend may be more appropriate.
Check out our most popular products for sale to compare available formulations.
What Should Buyers Look for When Sourcing This Blend?
Quality control is non-negotiable when purchasing any peptide blend. Here's a checklist:
- Third-party HPLC testing confirming purity above 98%
- Mass spectrometry verification of correct molecular weights for both tesa and ipamorelin
- Certificate of Analysis (COA) included with every batch
- Clear labeling of the exact amount (in mg) of each peptide component per vial
- Proper lyophilization resulting in a clean, white powder cake
- Cold chain shipping to preserve peptide integrity during transit
- Vendor reputation with verifiable reviews and transparent lab testing practices
Look for suppliers that meet lab-tested peptide standards and provide full documentation.
FAQ
Is the Tesa/IPA blend peptide FDA-approved?
No. Tesamorelin alone is FDA-approved (as Egrifta) for HIV-associated lipodystrophy. The blend formulation with ipamorelin is sold for research purposes only and has no FDA approval.
Can the Tesa/IPA blend peptide be used for bodybuilding?
The blend is classified as a research chemical. Published research on tesa dosage in bodybuilding contexts discusses the individual compound, but the blend itself is not approved for athletic or therapeutic use.
What is the typical shelf life of a lyophilized Tesa/IPA blend?
When stored at -20°C in lyophilized form, most peptide blends maintain stability for 12-24 months. Once reconstituted, refrigerate at 2-8°C and use within 4-6 weeks for best results.
Does ipamorelin cause hunger like other ghrelin receptor agonists?
Ipamorelin is more selective than earlier secretagogues like GHRP-6. Research indicates it produces significantly less appetite stimulation, though mild hunger has been reported anecdotally.
How is the blend reconstituted?
Typically with bacteriostatic water. Gently swirl the vial rather than shaking to avoid denaturing the peptides. Specific volumes depend on the total peptide content per vial and the desired concentration per unit.
What's the difference between Tesa/IPA and Tesa/CJC/IPA?
The triple blend adds CJC-1295, a modified GHRH analog with a drug affinity complex (DAC) that extends its half-life. This means GH elevation is sustained longer. The Tesa/CJC/IPA 12mg blend is a popular alternative for researchers wanting extended-duration protocols.
Are there side effects documented in research?
Tesamorelin clinical trials reported injection site reactions, joint pain, and peripheral edema as the most common adverse events. Ipamorelin studies noted transient headache and mild nausea at higher doses. Blend-specific side effect data is not available from controlled trials.
Where can I buy a Tesa/IPA blend peptide?
From reputable peptide suppliers that provide third-party testing and COAs. Verify that the vendor ships with cold chain packaging and clearly labels blend ratios. See our most popular products for sale for current availability.
Conclusion
The Tesa/IPA blend peptide represents one of the more evidence-grounded peptide combinations available for research, largely because tesa carries FDA-approved clinical trial data and ipamorelin has a well-documented selectivity profile. The dual-pathway mechanism of targeting both GHRH and ghrelin receptors provides a clear rationale for studying synergistic GH release.
Actionable next steps for researchers and buyers:
- Define the specific research question before choosing between a two-component blend and a triple or quad blend.
- Source only from vendors providing batch-specific COAs with HPLC and mass spectrometry data.
- Review the published literature on each individual component to set appropriate dosing parameters.
- Store lyophilized peptides at -20°C and reconstituted solutions at 2-8°C.
- Stay current with new developments in peptide research as the field evolves rapidly.
The blend is a research tool, not a therapeutic product. Treat it with the rigor any serious research compound deserves.
References
- Falutz J, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine, 2007.
- Falutz J, et al. "Effects of tesa on body composition and metabolic parameters." Journal of Clinical Endocrinology & Metabolism, 2008.
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998.
- Baker LD, et al. "Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults." Archives of Neurology, 2012.
- Anderson NB, et al. "The effect of ipamorelin on bone in adult and neonatal rats." Bone, 2001.
- Bowers CY. "Growth hormone-releasing peptide (GHRP)." Cellular and Molecular Life Sciences, 1998.
Tags: Tesa/IPA blend peptide, tesa ipamorelin blend, peptide blends research, growth hormone secretagogue, tesa peptide, ipamorelin peptide, GH releasing peptides, peptide stacking, biohacking peptides, longevity research, research peptides for sale, body composition peptides